A multicenter randomized phase 2 trial dubbed DURABLE found that maintenance durvalumab plus anlotinib performed better than durvalumab monotherapy in extensive-stage small-cell lung cancer. The study evaluated efficacy and biomarker signals as part of an approach to intensify maintenance therapy in a setting with limited long-term options.